Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4294706 | 0.87 | TSHR (0.50) | TSHRMAPK1KMT2ACYP1A2KDM4E | |
| SCHEMBL26326238 | 0.85 | TSHR (0.63) | TSHRMAPK1KMT2ACYP1A2KDM4E | |
| SCHEMBL13234849 | 0.84 | KMT2A (0.54) | TSHRKMT2AADRB2ADRB1USP2 | |
| SCHEMBL4347668 | 0.82 | KMT2A (0.53) | TSHRKMT2AARADRB2ADRB1 | |
| SCHEMBL772842 | 0.82 | KMT2A (0.57) | TSHRKMT2AADRB2ADRB1ALOX15 | |
| SCHEMBL16002431 | 0.82 | TSHR (0.71) | TSHRMAPK1KMT2ACYP1A2KDM4E | |
| SCHEMBL29366942 | 0.82 | TSHR (0.71) | TSHRMAPK1KMT2ACYP1A2KDM4E | |
| SCHEMBL1496789 | 0.82 | TSHR (0.71) | TSHRMAPK1KMT2ACYP1A2KDM4E | |
| SCHEMBL14896741 | 0.82 | TSHR (0.71) | TSHRMAPK1KMT2ACYP1A2KDM4E | |
| SCHEMBL9934643 | 0.81 | TSHR (0.51) | TSHRMAPK1KMT2ACYP1A2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110306773-A1 | PROCESS FOR PREPARATION OF METAXALONE | RA CHEM PHARMA LIMITED (IN) | 2011-12-15 | — | — | US | claimed |
| US-20110306773-A1 | PROCESS FOR PREPARATION OF METAXALONE | RA CHEM PHARMA LIMITED (IN) | 2011-12-15 | — | — | US | disclosed |
| US-20110306773-A1 | PROCESS FOR PREPARATION OF METAXALONE | RA CHEM PHARMA LIMITED (IN) | 2011-12-15 | — | — | US | disclosed |
| US-20110306773-A1 | PROCESS FOR PREPARATION OF METAXALONE | RA CHEM PHARMA LIMITED (IN) | 2011-12-15 | — | — | US | disclosed |
| US-20110306773-A1 | PROCESS FOR PREPARATION OF METAXALONE | RA CHEM PHARMA LIMITED (IN) | 2011-12-15 | — | — | US | disclosed |
| US-20090270469-A1 | SUBSTITUTED OXAZOLIDINONES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270469-A1 | SUBSTITUTED OXAZOLIDINONES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| US-20090270469-A1 | SUBSTITUTED OXAZOLIDINONES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2009132119-A2 | SUBSTITUTED OXAZOLIDINONES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009132119-A2 | SUBSTITUTED OXAZOLIDINONES | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20050075505-A1 | Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone | GANDHI BIREN JAIPRAKASH (IN) | 2005-04-07 | — | — | US | disclosed |
| WO-2003061552-A2 | NOVEL PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 5-(3,5-DIMETHYLPHENOXY)METHYL-2-OXAZOLIDINONE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2003-07-31 | — | — | WO | disclosed |
| US-6538142-B1 | Reacting epichlorohydrin and 3,5-dimethylphenol; reacting with benzylamine; reduction with hydrogen in ammonia; cyclization by reacting with dimethyl carbonate in base | FARCHEMIA S.R.L. (IT) | 2003-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270469-A1 | SUBSTITUTED OXAZOLIDINONES | MUSK, MYLK2, PYGM | TSHR 1583/4885MAPK1 2755/4885KMT2A 3965/4885 |
| US-20110306773-A1 | PROCESS FOR PREPARATION OF METAXALONE | MTX1, XDH, MTX2 | TSHR 2851/4885MAPK1 298/4885KMT2A 2417/4885 |
| US-20050075505-A1 | Novel process for the preparation of substantially pure 5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone | ODC1, OGFOD1, KMO | TSHR 2413/4885MAPK1 1239/4885KMT2A 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.